PCRX Pacira BioSciences Inc

Price (delayed)

$20.04

Market cap

$932.78M

P/E Ratio

13.18

Dividend/share

N/A

EPS

$1.52

Enterprise value

$1.33B

Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local ...

Highlights
The company's quick ratio has surged by 69% YoY and by 16% QoQ
The company's net income has surged by 68% QoQ

Key stats

What are the main financial stats of PCRX
Market
Shares outstanding
46.55M
Market cap
$932.78M
Enterprise value
$1.33B
Valuations
Price to book (P/B)
1.04
Price to sales (P/S)
1.37
EV/EBIT
11.48
EV/EBITDA
6.99
EV/Sales
1.95
Earnings
Revenue
$681.75M
EBIT
$115.85M
EBITDA
$190.25M
Free cash flow
$173.19M
Per share
EPS
$1.52
Free cash flow per share
$3.72
Book value per share
$19.19
Revenue per share
$14.66
TBVPS
$20.46
Balance sheet
Total assets
$1.58B
Total liabilities
$691.16M
Debt
$581.78M
Equity
$892.16M
Working capital
$449.67M
Liquidity
Debt to equity
0.65
Current ratio
5.81
Quick ratio
4.58
Net debt/EBITDA
2.09
Margins
EBITDA margin
27.9%
Gross margin
73.1%
Net margin
10.3%
Operating margin
15.3%
Efficiency
Return on assets
4.5%
Return on equity
8.3%
Return on invested capital
9.1%
Return on capital employed
7.8%
Return on sales
17%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCRX stock price

How has the Pacira BioSciences stock price performed over time
Intraday
-1.09%
1 week
-0.89%
1 month
-29.39%
1 year
-46.09%
YTD
-40.6%
QTD
-29.95%

Financial performance

How have Pacira BioSciences's revenue and profit performed over time
Revenue
$681.75M
Gross profit
$498.69M
Operating income
$103.98M
Net income
$70.47M
Gross margin
73.1%
Net margin
10.3%
The company's operating income has surged by 163% YoY and by 19% QoQ
PCRX's operating margin has soared by 159% YoY and by 18% QoQ
The company's net income has surged by 68% QoQ
Pacira BioSciences's net margin has soared by 66% from the previous quarter

Growth

What is Pacira BioSciences's growth rate over time

Valuation

What is Pacira BioSciences stock price valuation
P/E
13.18
P/B
1.04
P/S
1.37
EV/EBIT
11.48
EV/EBITDA
6.99
EV/Sales
1.95
Pacira BioSciences's EPS has surged by 67% QoQ
PCRX's P/B is 70% below its 5-year quarterly average of 3.5 and 41% below its last 4 quarters average of 1.8
The equity has increased by 16% year-on-year and by 2.5% since the previous quarter
The price to sales (P/S) is 67% lower than the 5-year quarterly average of 4.2 and 40% lower than the last 4 quarters average of 2.3

Efficiency

How efficient is Pacira BioSciences business performance
Pacira BioSciences's ROA has soared by 67% from the previous quarter
PCRX's ROE has soared by 63% since the previous quarter
Pacira BioSciences's ROIC has increased by 42% from the previous quarter
Pacira BioSciences's return on sales has increased by 40% QoQ

Dividends

What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCRX.

Financial health

How did Pacira BioSciences financials performed over time
The total assets is 129% greater than the total liabilities
The company's quick ratio has surged by 69% YoY and by 16% QoQ
The current ratio has soared by 52% YoY and by 11% from the previous quarter
Pacira BioSciences's debt is 35% less than its equity
Pacira BioSciences's debt to equity has decreased by 20% YoY and by 3% from the previous quarter
The equity has increased by 16% year-on-year and by 2.5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.